Results 211 to 220 of about 58,972 (283)

An Immune Microenvironment-Integrated Intestinal-on-a-Chip Model for Investigating Immunopathogenesis in Inflammatory Bowel Disease. [PDF]

Molecules
Ying S, Xu H, Xu Y, Mi X.
europepmc   +1 more source

Irritable Bowel Syndrome Prevalence in Patients with Inflammatory Bowel Disease in Remission: Single-Center Experience. [PDF]

Clin Exp Gastroenterol
Golubovic O, Knezevic Ivanovski T, Kralj D, Mitrovic M, Milić A, Svorcan P, Markovic S.   +6 more
europepmc   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, Volume 65, Issue 7, Page 1376-1382, July 2026.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

A mathematical model to simulate the biological action of Infliximab on TNF- α in patients with Inflammatory Bowel Disease: the critical role of drug clearance. [PDF]

Bull Math Biol
Portillo AM, De Prado Á, Soares AJ.
europepmc   +1 more source

Role of Gram‐Negative Bacterial Infections in Acute‐On‐Chronic Liver Failure

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Acute‐on‐chronic liver failure (ACLF) is a systemic disease characterised by an acute clinical deterioration of pre‐existing liver cirrhosis leading to multiple organ failure due to systemic inflammation. It may be triggered by the translocation of bacteria and bacterial compounds across the gut barrier.
Camilla Cadoli, Volker Müller, Christoph Welsch, Heiko Mühl, Jonel Trebicka, Volkhard A. J. Kempf   +5 more
wiley   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna, Jiezhun Gu, Yi‐Ju Li, Huiman Barnhart, Dina Halegoua‐DeMarzio, Herbert L. Bonkovsky, A. Sidney Barritt, Jean P. Molleston, Naga P. Chalasani, Marwan Ghabril   +9 more
wiley   +1 more source

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan. [PDF]

J Pharm Policy Pract
Mamiya H, Fukasawa T, Kawakami K.
europepmc   +1 more source

Biologic dose escalation in inflammatory bowel disease in the United States. [PDF]

J Manag Care Spec Pharm
Chapman C, Vadhariya A, Bires N, Brady BL, Creveling T, Ross R, Evans KA, Panni T, Chan-Diehl FW, McGinnis K.   +9 more
europepmc   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1787-1808, June 2026.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial. [PDF]

Ther Adv Gastroenterol
Schreiber S, Danese S, Vermeire S, Leong RW, Pradhan V, Singh RSP, Yu D, Messing D, Neubert H, Palandra J, Tehlirian C, Gale JD.   +11 more
europepmc   +1 more source